• Bio-Techne is expected to report a year-over-year increase in earnings with projected revenues of $315.2 million and an EPS increase of 6.3%.
• The company has exceeded earnings expectations in three of the last four quarters, with an average surprise of 5.37%.

Bio-Techne is set to release its third-quarter fiscal 2025 results on May 7. The company is expected to report a year-over-year increase in earnings, driven by higher revenues. The Zacks Consensus Estimate projects revenues to reach $315.2 million, a 3.9% increase from the previous year. The EPS is anticipated to improve by 6.3%, reaching 51 cents.

In the previous quarter, Bio-Techne reported an adjusted EPS of 42 cents, surpassing the Zacks Consensus Estimate by 10.5%. The company has consistently exceeded earnings expectations in three of the last four quarters, with an average surprise of 5.37%. This track record has set high expectations for the upcoming earnings report.

The market is closely monitoring Bio-Techne's performance, as surpassing expectations could lead to a rise in the stock price. Conversely, failing to meet these expectations might result in a decline. The sustainability of any price change will depend on management's discussion of business conditions during the earnings call.

Bio-Techne's current stock price is $50.72, with a market capitalization of approximately $8.02 billion. The stock has fluctuated between a low of $49.69 and a high of $51.04 today. Over the past year, TECH has reached a high of $85.57 and a low of $46.01. The upcoming earnings report will be crucial in determining the stock's immediate price movement.